Skip to Main Content

Paper Details

Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63).
J Immunother Cancer
13
2021
Author NameAffiliation
Craig L SlingluffUniversity of Virginia School of Medicine
Craig L SlingluffUniversity of Virginia Cancer Center
Kimberly A Chianese-BullockUniversity of Virginia School of Medicine
Kimberly A Chianese-BullockUniversity of Virginia Cancer Center
Mark E SmolkinUniversity of Virginia School of Medicine
  • 1 - 5

Datasets

Release 1.2